PEDIATRIC CANCER
ADVANCED TREATMENT FOR FAMILIES

Paediatric oncology is a distinct medical specialty — not scaled-down adult oncology. The cancer types, biology, treatment protocols, dosing regimens, and long-term goals are all fundamentally different from adult cancer management.

“Treating a child with adult cancer dosing protocols is not just suboptimal — it is potentially harmful. Paediatric oncologists use dosing and supportive care developed specifically for the developing child.”

• Biological Origin

  Most adult cancers result from accumulated environmental exposures over decades. Childhood cancer arises from developmental abnormalities — often characteristic chromosomal translocations or fusion genes occurring during rapid fetal and childhood development. Lifestyle factors play almost no role.

• Chemosensitivity

  Childhood cancers are generally highly chemosensitive — rapidly dividing developmental cells respond dramatically to cytotoxic therapy. This drives high cure rates but also creates unique vulnerability to long-term chemotherapy effects on developing organs and the CNS.

• Survivorship Is Central

  Most cured childhood cancer patients face 50–70 years of post-treatment life. Every treatment decision is weighed against potential late effects at age 20, 40, or 60 — cardiac damage from anthracyclines, pulmonary fibrosis from radiation, neurocognitive effects of CNS therapy, secondary malignancies.

• The Family Is the Unit of Care

  Paediatric cancer care is inseparable from family care. The diagnosis affects parents, siblings, and extended family. Leading paediatric cancer centres provide family support services as part of the treatment programme — not an afterthought.

The distribution of cancer types in children is entirely different from adults — leukaemias, brain tumours, and embryonal tumours predominate.

Modern paediatric oncology has moved well beyond standard chemotherapy. CAR-T cell therapy, molecular targeted drugs, proton beam radiation, and precision genomics have transformed outcomes for many childhood cancers.

• CAR-T Cell Therapy (Tisagenlecleucel / Kymriah)

  FDA-approved for paediatric and young adult r/r B-cell ALL — achieving 80%+ remission rates where standard salvage therapy achieves <30%. Also approved for r/r DLBCL. Multiple paediatric CAR-T trials active in China for ALL, NHL, and solid tumours. Access through CancerFax at substantially lower cost than the US.

• Proton Beam Therapy

  The preferred radiation modality for paediatric CNS tumours, craniospinal irradiation, head/neck tumours, and spinal tumours. Exit dose from conventional X-rays causes long-term cardiac, pulmonary, endocrine, and neurocognitive damage in growing children. Proton craniospinal irradiation dramatically reduces these exposures.

• Molecular Testing and Precision Oncology

  Comprehensive genomic profiling (NGS) is now standard for paediatric brain tumours, sarcomas, and refractory leukaemias. Methylation profiling reclassifies paediatric brain tumours. NTRK fusions occur at high rates in specific paediatric cancers — larotrectinib achieves 75%+ response regardless of histology.

• Clinical Trials: Central to Paediatric Care

  For childhood cancers, clinical trial participation is not a last resort — it is the standard of care at most leading centres. COG, SIOPE, and national paediatric oncology groups run multi-institutional trials that define treatment standards. Rare paediatric cancers often have global trials as the only source of advanced therapy.

The majority of childhood cancer survivors face decades of post-treatment life. Long-term follow-up is not optional — it is essential for identifying and managing late effects before they become irreversible.

• Cardiac Late Effects

  Anthracycline chemotherapy causes dose-dependent cardiomyopathy — risk increases with cumulative dose and radiation exposure to the cardiac silhouette. Annual cardiac surveillance (ECG, echocardiogram) is standard for long-term survivors who received anthracyclines or chest radiation.

• Neurocognitive Effects

  CNS radiation and intrathecal chemotherapy can cause neurocognitive late effects — memory, processing speed, and executive function — particularly in children treated under age 7. Neuropsychological monitoring and educational support are part of survivorship care at leading centres.

• Endocrine Late Effects

  Growth hormone deficiency, hypothyroidism, adrenal insufficiency, and gonadal dysfunction are common after cranial radiation and certain chemotherapy regimens. Annual endocrine review from the first year of follow-up is standard at paediatric oncology survivorship clinics.

• Secondary Malignancies

  Radiation and alkylating agents increase the risk of secondary malignancies — most commonly secondary AML/MDS (5–10 years after alkylating agent/topoisomerase inhibitor exposure) and solid tumours in the radiation field (10–30 years later). Lifelong cancer surveillance is part of survivorship care.

Paediatric cancer requires specialist care — and families often need help navigating a complex, internationally distributed system of expertise.

1. 1

   Paediatric Case Review

   Comprehensive review of pathology, molecular testing, imaging, and treatment history by paediatric oncology specialists — identifying the exact cancer subtype, risk stratification, and appropriate treatment pathway.

2. 2

   Specialist Centre Matching

   Identification of the most appropriate paediatric oncology centre for the specific diagnosis — including COG-affiliated centres globally, leading Chinese paediatric oncology programmes, and specialist centres for sarcoma, CNS, or haematological malignancies.

3. 3

   CAR-T and Clinical Trial Access

   Identification of enrolling paediatric CAR-T trials and other advanced therapy trials globally, including China — where multiple paediatric CAR-T and immunotherapy trials are actively enrolling at a fraction of Western commercial costs.

4. 4

   Proton Therapy Coordination

   Facilitation of paediatric proton therapy at SPHIC Shanghai or other particle therapy centres — from eligibility assessment and remote dosimetric planning review to travel logistics and in-country support.

5. 5

   Family Support Throughout

   Comprehensive support for parents and siblings throughout the treatment journey — including accommodation, interpretation, school-readmission planning, and connection with paediatric psycho-oncology services at the treating centre.

Each page covers one paediatric oncology topic in depth.

Frequently Asked Questions